Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.

Abstract:

INTRODUCTION:Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AIMS:To investigate DAPT duration after hospital discharge for ACS in Spain. RESULTS:Data from patients enrolled in the Spanish cohort of the EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study (NCT01171404) were analyzed for changes to antithrombotic medication up to 2 years postdischarge according to index event diagnosis and patient characteristics. Deaths, coronary events, and bleeding events were analyzed over the same period. Overall, a high proportion of patients remained on DAPT at 2 years (53.1%). Among patients who experienced any on-treatment bleeding event, almost two-thirds remained on DAPT at the end of follow-up. Patients >65 years, diabetic, or those that were medically managed were more likely to continue with DAPT until 2 years following discharge. At 2 years, the incidence of bleeding events requiring hospitalization was low compared with the incidence of coronary events (1.4% vs 6.6%). There was a numerical reduction in coronary events, but no increase in bleeding events, with DAPT continuation compared with single antiplatelet therapy. CONCLUSIONS:More than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritizes ischemic risk reduction over bleeding risk in patients with ACS, according to patient's risk profile.

journal_name

Cardiovasc Ther

authors

Bardají A,Leal M,Arrarte V,Garcia-Moll X,Pérez de Isla L,Bueno H

doi

10.1111/1755-5922.12237

subject

Has Abstract

pub_date

2017-04-01 00:00:00

issue

2

eissn

1755-5914

issn

1755-5922

journal_volume

35

pub_type

杂志文章,多中心研究
  • Clinical application of adult stem cells for therapy for cardiac disease.

    abstract:INTRODUCTION:Cardiovascular disease is a major cause of death worldwide. Different medical and surgical therapeutic options are well established, but a significant number of patients are not amenable to standard therapeutic options. Cell-based therapies after clinical application have shown different results in recent ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12032

    authors: Ghodsizad A,Ruhparwar A,Bordel V,Mirsaidighazi E,Klein HM,Koerner MM,Karck M,El-Banayosy A

    更新日期:2013-12-01 00:00:00

  • Warfarin persistence among atrial fibrillation patients - why is treatment ended?

    abstract:BACKGROUND AND AIM:Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). Studies mainly focused on whether the proportion of warfarin persistence and discontinuation are clinically appropriate are absent. This study evaluates warfarin persistence with focus on predictors for, a...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12224

    authors: Björck F,Ek A,Johansson L,Själander A

    更新日期:2016-12-01 00:00:00

  • Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japane

    abstract:BACKGROUND:Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore,...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12027

    authors: Kawashiri MA,Yamagishi M,Sakamoto T,Takayama T,Hiro T,Daida H,Hirayama A,Saito S,Yamaguchi T,Matsuzaki M,COSMOS Investigators.

    更新日期:2013-12-01 00:00:00

  • The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.

    abstract:AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12178

    authors: Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

    更新日期:2016-06-01 00:00:00

  • Atorvastatin attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats postmyocardial infarction.

    abstract:OBJECTIVES:Inflammation after myocardial infarction (MI) causes cardiac nerve sprouting and consequent ventricular arrhythmias (VAs). Macrophages, as major immune cells, are involved in the entire inflammation response process and serve as a link between inflammation and sympathetic hyperinnervation by regulating nerve...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12193

    authors: Yang N,Cheng W,Hu H,Xue M,Li X,Wang Y,Xuan Y,Li X,Yin J,Shi Y,Yan S

    更新日期:2016-08-01 00:00:00

  • Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

    abstract:BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors an...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12458

    authors: Zanella L,Zoppellaro G,Marigo L,Denas G,Padayattil Jose S,Pengo V

    更新日期:2018-10-01 00:00:00

  • Regenerative therapy in peripheral artery disease.

    abstract::Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore, new strategies need to b...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00105.x

    authors: Germani A,Di Campli C,Pompilio G,Biglioli P,Capogrossi MC

    更新日期:2009-01-01 00:00:00

  • Multimodal Interventions to Enhance Adherence to Secondary Preventive Medication after Stroke: A Systematic Review and Meta-Analyses.

    abstract:INTRODUCTION:Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence. We performed a systematic review and meta-analysis to describe the efficacy of strategies to improve adherence to stroke secondary prevention. MET...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12176

    authors: Al AlShaikh S,Quinn T,Dunn W,Walters M,Dawson J

    更新日期:2016-04-01 00:00:00

  • Diagnosis and management of atrial fibrillation: an overview.

    abstract::Atrial fibrillation (AF) has been defined as the new cardiovascular "epidemic". Its prevalence is rising in developed countries, and the associated social and economic costs are high. In the last few years, there has been an increasing interest in understanding the mechanisms of AF and its management. New pharmacother...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12090

    authors: Romero I,Nedios S,Kriatselis C

    更新日期:2014-10-01 00:00:00

  • Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.

    abstract:BACKGROUND:Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Beta-blockers are considered the most suitable treatment for such complication. AIM OF THE STUDY:The objective of this study was to evaluate the hemodynam...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12182

    authors: Santoro F,Ieva R,Ferraretti A,Fanelli M,Musaico F,Tarantino N,Martino LD,Gennaro LD,Caldarola P,Biase MD,Brunetti ND

    更新日期:2016-06-01 00:00:00

  • Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.

    abstract:AIMS:Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS:In a prosp...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12270

    authors: Xanthopoulou I,Davlouros P,Deftereos S,Hamilos M,Sitafidis G,Kanakakis I,Vavouranakis M,Goudevenos J,Lekakis J,Alexopoulos D

    更新日期:2017-08-01 00:00:00

  • Prevention of atrial fibrillation in cardiac surgery: time to consider a multimodality pharmacological approach.

    abstract::Atrial fibrillation (AF) is very common within the first 5 days of cardiac surgery. It is associated with significant morbidity including stroke, ventricular arrhythmias, myocardial infarction, heart failure, acute kidney injury, prolonged hospital stay, and also short- and long-term mortality. The underlying mechanis...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00117.x

    authors: Ho KM,Lewis JP

    更新日期:2010-04-01 00:00:00

  • Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.

    abstract:BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12277

    authors: Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

    更新日期:2017-10-01 00:00:00

  • Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.

    abstract:INTRODUCTION:In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared to aspirin alone was associated with fewer endoscopic gastric and duodenal ulcers in patients requiring aspirin therapy for secondary cardiovascular disease (CVD...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12172

    authors: Goldstein JL,Whellan DJ,Scheiman JM,Cryer BL,Eisen GM,Lanas A,Fort JG

    更新日期:2016-04-01 00:00:00

  • Combating Donor Organ Shortage: Organ Care System Prolonging Organ Storage Time and Improving the Outcome of Heart Transplantations.

    abstract:Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1155/2019/9482797

    authors: Sunjaya AF,Sunjaya AP

    更新日期:2019-04-01 00:00:00

  • Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.

    abstract:INTRODUCTION:The effectiveness of statin pretreatment in reducing the incidence of contrast-induced nephropathy (CIN) has been examined in some observational and randomized studies, yielding controversial results. AIM:This study sought to evaluate the role of atorvastatin in prevention of CIN in diabetic patients with...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12108

    authors: Shehata M,Hamza M

    更新日期:2015-04-01 00:00:00

  • Aspirin resistance and compliance with therapy.

    abstract:INTRODUCTION:Aspirin resistance is associated with increased cardiovascular risk in aspirin-treated patients. Poor compliance may explain many cases of "resistance," yet few clinical studies have used objective measurement of therapy compliance. We did so in a case-controlled study. METHODS:We enrolled patients within...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2010.00188.x

    authors: Dawson J,Quinn T,Rafferty M,Higgins P,Ray G,Lees KR,Walters MR

    更新日期:2011-10-01 00:00:00

  • Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.

    abstract:INTRODUCTION:Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS:We use observational long-term data on PA...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12281

    authors: Ascha M,Zhou X,Rao Y,Minai OA,Tonelli AR

    更新日期:2017-10-01 00:00:00

  • Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials.

    abstract:INTRODUCTION:Statins are known to prevent heart failure (HF). However, it is unclear whether statins as class or type (lipophilic or hydrophilic) improve outcomes of established HF. AIMS:The current meta-analysis was performed to compare the treatment effects of lipophilic and hydrophilic statins on inflammation and c...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12150

    authors: Bonsu KO,Reidpath DD,Kadirvelu A

    更新日期:2015-12-01 00:00:00

  • Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.

    abstract::Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, stroke, blindness, and end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Recent clinical studies have substantiated the concept of "hyperglycemic...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1527-3466.2007.00038.x

    authors: Yamagishi S,Nakamura K,Matsui T,Ueda S,Noda Y,Imaizumi T

    更新日期:2008-04-01 00:00:00

  • Epac-Rap1-activated mesenchymal stem cells improve cardiac function in rat model of myocardial infarction.

    abstract:INTRODUCTION:Rap1, a member of Ras superfamily of small GTP-binding proteins, is involved in cardiovascular biology in numerous ways. It is an evolutionary conserved regulator of adhesion, polarity, differentiation and growth. AIMS:Our aim was to analyze Rap1-activated rat bone marrow mesenchymal stem cells (MSCs) for...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12248

    authors: Khan I,Ali A,Akhter MA,Naeem N,Chotani MA,Iqbal H,Kabir N,Atiq M,Salim A

    更新日期:2017-04-01 00:00:00

  • Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications.

    abstract:AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12085

    authors: Choo WK,Turpie D,Milne K,Davidson L,Elofuke P,Whitfield J,Broadhurst P

    更新日期:2014-10-01 00:00:00

  • Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology.

    abstract::Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00070.x

    authors: Lim TK,Choy AJ,Khan F,Belch JJ,Struthers AD,Lang CC

    更新日期:2009-04-01 00:00:00

  • Insulin resistance: a potential new target for therapy in patients with heart failure.

    abstract::There is increasing evidence to suggest that chronic heart failure (CHF) is an insulin resistant (IR) state and that the degree of IR correlates with the severity and mortality of CHF. The pathophysiology of IR in CHF has yet to be fully defined. Additionally, it remains to be determined if IR is merely a marker refle...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00053.x

    authors: Wong AK,AlZadjali MA,Choy AM,Lang CC

    更新日期:2008-10-01 00:00:00

  • Efficacy and safety of a second-generation biodegradable polymer sirolimus-eluting stent: One-year results of the CREDIT 2 trial.

    abstract:AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/1755-5922.12327

    authors: Xu K,Han Y,Xu B,Yang Y,Wang G,Li H,Sun Y,Tao L,Wang H,Yuan Z,Liu H,Liu J,Jia Y,Ma G,Fu G,Li X,Li S,Wang S,Pu K,CREDIT 2 Investigators.

    更新日期:2018-06-01 00:00:00

  • Circulating CTRP1 Levels Are Increased and Associated with the STOD in Essential Hypertension in Chinese Patients.

    abstract::This study aimed to investigate the correlation between complement C1q tumor necrosis factor-related protein 1 (CTRP1) and subclinical target organ damage (STOD) in essential hypertension (EH). 720 patients were enrolled in this study, including 360 healthy subjects and 360 patients with EH. The EH group included 183 ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2019/4183781

    authors: Su Z,Tian S,Liang W

    更新日期:2019-06-02 00:00:00

  • Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.

    abstract::Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart fr...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12101

    authors: Mohan M,McSwiggan S,Baig F,Rutherford L,Lang CC

    更新日期:2015-02-01 00:00:00

  • Cell-based therapy for chronic ischemic heart disease--a clinical perspective.

    abstract::In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00214.x

    authors: Perin EC,Silva GV

    更新日期:2011-06-01 00:00:00

  • Aspirin responsiveness changes in obese patients following bariatric surgery.

    abstract:AIMS:Bariatric surgery has emerged as a promising treatment option for weight loss and to counter the metabolic consequences of obesity. Obesity has been linked to a hyperaggregable state, as well as a blunted response to aspirin. This pilot study assessed the hypothesis that bariatric surgery would lead to an improvem...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12268

    authors: Norgard NB,Monte SV,Fernandez SF,Ma Q

    更新日期:2017-08-01 00:00:00

  • Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

    abstract::Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in clinical practice, increasing in prevalence with age. AF is often associated with structural heart disease, although a significant proportion has no detectable heart disease. In the last 2 decades, there has been an increase of 6...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00216.x

    authors: Escobar C,Barrios V,Jimenez D

    更新日期:2010-10-01 00:00:00